Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.290 +0.090 (+4.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,290,930
Open 2.220
Bid (Size) 2.280 (2)
Ask (Size) 2.300 (10)
Prev. Close 2.200
Today's Range 2.180 - 2.325
52wk Range 0.9101 - 4.190
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss
Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for... 
Via Chartmill
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire

Performance

YTD
+74.8%
+74.8%
1 Month
-19.6%
-19.6%
3 Month
+52.7%
+52.7%
6 Month
+94.1%
+94.1%
1 Year
-41.6%
-41.6%

More News

Read More
Can This Beaten-Down Stock Bounce Back?
Via The Motley Fool
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
Via The Motley Fool
Topics Workforce
2 Beaten-Down Stocks to Avoid
Via The Motley Fool
Earnings Scheduled For May 12, 2025
Via Benzinga
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Via Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
Via The Motley Fool
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Via Investor's Business Daily
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
1 Stock Down 97% That Could Double, According to Wall Street
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Editas Medicine: A Cautionary Tale for Investors
Via The Motley Fool
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
The Future of Healthcare: 10 Predictions For The Next Decade
Via MarketMinute
Topics Artificial Intelligence
Editas Medicine Announces Chief Financial Officer Transition
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential
Via Stocktwits
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2025
Via Benzinga

Frequently Asked Questions

Is Editas Medicine, Inc. - Common Stock publicly traded?
Yes, Editas Medicine, Inc. - Common Stock is publicly traded.
What exchange does Editas Medicine, Inc. - Common Stock trade on?
Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Editas Medicine, Inc. - Common Stock?
The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market
What is the current price of Editas Medicine, Inc. - Common Stock?
The current price of Editas Medicine, Inc. - Common Stock is 2.290
When was Editas Medicine, Inc. - Common Stock last traded?
The last trade of Editas Medicine, Inc. - Common Stock was at 08/12/25 04:00 PM ET
What is the market capitalization of Editas Medicine, Inc. - Common Stock?
The market capitalization of Editas Medicine, Inc. - Common Stock is 186.94M
How many shares of Editas Medicine, Inc. - Common Stock are outstanding?
Editas Medicine, Inc. - Common Stock has 187M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.